INTRODUCTION
 It is essential to develop reliable, well-defined and clinically relevant endpoints that measure tangible benefits for patients in clinical trials of antibacterial drugs in accordance with the FDA Guidance for patientreported outcome (PRO) measures and hospital-acquired bacterial pneumonia (HABP). 1 Currently used endpoints in HABP clinical trials such as clinical response, clinical cure, and time to event, are only indirect measures of treatment benefit and have not been validated.
 Currently there is no HABP PRO instrument to capture additional symptoms of how patients feel, function, or survive.
 The Foundation for the National Institutes of Health (FNIH) Biomarkers
Consortium and ICON plc are developing clinically relevant endpoints that measure tangible benefits for patients in clinical trials of antibacterial drugs.
PURPOSE
 The goal of this study was to explore HABP symptoms and impacts as reported by patients, and to develop a draft PRO symptom instrument using methods in-line with the FDA PRO Guidance (2009). 2  The information gathered in concept elicitation (CE) interviews, expert reviews, and cognitive debriefing (CD) interviews will be used to modify and expand the conceptual framework which will form the basis of a new HABP-specific PRO instrument.
METHODS
 CE was conducted by telephone interviews with patients within 10 days of HABP diagnosis. Data were analyzed on a rolling basis using an iterative process to identify themes and concepts and recorded in a saturation grid.
 After 8 interviews, a point of saturation was achieved as no new pneumonia concepts had emerged. Overall, concepts endorsed by HABP patients were similar to concepts reported by patients in our previous study to develop a symptom PRO measure for communityacquired bacterial pneumonia (CABP) (See PIN 84, ISPOR 2015). 3  A decision was made to begin combined CE and CD interviews using items from our previously developed CABP PRO measure due to the overlap of symptoms and impacts between the two patient populations. In addition to eliciting HABP related concepts, the combined CE/CD interviews are being conducted to assess item readability, relevance, comprehensiveness, and content validity of the original CABP PRO items with the HABP patient population.  To date, 8 patients have participated in CE interviews and 3 patients have participated in combined CE/CD interviews. Demographics and patient characteristics are reported below in Table 1 .  Preliminary evidence may suggest the use of a unified PRO instrument that can be used to aid the evaluation of new bacterial treatments for both HABP and CABP.
 After completion of the PRO instrument development work described above, a daily symptom diary with established content validity will be ready for psychometric validation.
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